Investor Relations

Enabling Complex Cellular Engineering to Transform the Lives of Patients

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation^® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health.

Our Technology

Navigating the best route to development of groundbreaking cell therapies is an exciting challenge. At MaxCyte®, we’ve spent over 20 years honing our cell engineering expertise, optimizing static electroporation and innovating to create our Flow Electroporation® technology. We’ve perfected the art of the transfection workflow. Our collection of ExPERT™ instruments delivers engineering excellence, combining high efficiency and cell viability with seamless scalability. Our technology is empowering research journeys from concept to commercialization.

Learn More: https://maxcyte.com/our-technology/

A history of innovation driving cell engineering-based therapeutics

MaxCyte has pioneered the development of a cell-engineering platform based on Flow Electroporation® Technology. Originally conceived to meet the stringent demands of cell therapy applications – namely, the ability to safely and reproducibly modify human cells with high efficiency, low cytotoxicity and at the scale required to treat patients – MaxCyte has expanded the platform and applications to accelerate the development of small molecule drugs, biologics and vaccines, in addition to broadly enabling cell therapy applications.